Table 1.

Clinical efficacy of targeted therapies in breast cancer brain metastases

Regimen	Target	Breast cancer subtypes	CNS response rate	Reference
Afatinib	HER2/EGFR	HER2+	0%	Cortes et al, Lancet Oncol. 2015; 16:1700–1710
Neratinib	HER2/EGFR	HER2+	8%	Freedman et al, J Clin Oncol. 2016; 34:945–952
Neratinib + capecitabine	HER2/EGFR, antimetabolite	HER2+	49%	Freedman et al, J Clin Oncol. 35, no. 15_suppl (May 2017) 1005–1005
Tucatinib	HER2	HER2+	7%	Metzger et al, J Clin Oncol. 2016; 32:5s (suppl; abstr TPS660)
Tucatinib +/− capecitabine or trastuzumab	HER2, antimetabolite	HER2+	42%	Hamilton et al, Poster P5-20-1, SABCS 2017
Lapatinib	HER2	HER2+	6%	Lin et al, Clin Cancer Res. 2009; 15:1452–1459.
Lapatinib + capecitabine	HER2, antimetabolite	HER2+	18–38% (pre-treated); 66% (untreated)	Lin et al, J Neurooncol. 2011; 105:613–620. Bachelot et al, Lancet Oncol. 2013; 14:64–71.
Buparlisib + trastuzumab	PI3K + HER2	HER2+	11%	Pistilli et al., Breast Cancer Res Treat (2017).
Everolimus + trastuzumab + vinorelbine	mTOR + HER2 + anti-mitotic	HER2+	4%	Anders et al, J Clin Oncol 35, 2017 (suppl; abstr 1011)